AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16038387 — intervention group
Group type: COMPARATOR
Intervention: No dynamic bubble trap (DBT)
Number of subjects: 12
Study 12501880 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate 70 mg
Number of subjects: 288
Study 12501880 — intervention group
Group type: COMPARATOR
Intervention: Once-daily alendronate 10 mg
Number of subjects: 288
Study 10366909 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week postoperative immobilization
Number of subjects: 60
Study 10366909 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks postoperative immobilization
Number of subjects: 60
Study 7673615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day for 8 weeks (GU) or 6 weeks (DU)
Number of subjects: 88
Study 7673615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy of lansoprazole 30 mg/day and amoxicillin (AMPC) 1 g/day or clarithromycin (CAM) 400 mg/day for 2 weeks
Number of subjects: 88
Study 7673615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of lansoprazole 30 mg/day, AMPC 1 g/day, or CAM 400 mg/day, and metronidazole 500 mg/day for 2 weeks
Number of subjects: 88
Study 7673615 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 88
Study 2210280 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable plastic biopsy forceps
Number of subjects: 30
Study 2210280 — intervention group
Group type: COMPARATOR
Intervention: Reusable stainless steel forceps
Number of subjects: 30
Study 7032411 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (single intravenous dose)
Number of subjects: 203
Study 7032411 — intervention group
Group type: COMPARATOR
Intervention: Control (no metronidazole)
Number of subjects: 203
Study 29898141 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetylcysteine, vitamin C and selenium (600 mg, 1500 mg, 0.5 mg respectively) administered orally twice a day from the day before to 2 days after surgery
Number of subjects: 291
Study 29898141 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing administered)
Number of subjects: 291
Study 29898141 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (N‐acetylcysteine, vitamin C, selenium, and control)
Number of subjects: 291
Study 27227933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (9 mL/kg bicarbonate 154 mmol/L)
Number of subjects: 152
Study 27227933 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 152
Study 24703574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² with vitamin B12 and folic acid q3w
Number of subjects: 159
Study 24703574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² with vitamin B12 and folic acid q3w + Erlotinib 150 mg daily
Number of subjects: 159
Study 22386118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools for Getting Along (TFGA) curriculum
Number of subjects: 1296
Study 20544227 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio Frequency (RF)
Number of subjects: 2
Study 20544227 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 2
Study 18235116 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (100 to 800 mg daily)
Number of subjects: 60
Study 15881476 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin ER 1000 mg once daily
Number of subjects: 437
Study 12877665 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 30,000 IU subcutaneously once weekly (q.w.)
Number of subjects: 241
Study 12877665 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta 10,000 IU three-times weekly (t.i.w.)
Number of subjects: 241
Study 10490792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 4 months, 5 days/week, 40 minutes/day
Number of subjects: 79
Study 10490792 — intervention group
Group type: COMPARATOR
Intervention: Cessation of Exercise Training (no-ET) for 4 months after 4 months of ET
Number of subjects: 79
Study 7503620 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 480 mg/day
Number of subjects: 809
Study 7503620 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 200 mg/day
Number of subjects: 809
Study 1782922 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate 185.4 mg per day
Number of subjects: 50
Study 1782922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6890407 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine delivered by transdermal patch
Number of subjects: 0
Study 6890407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31917748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of viral suppression
Number of subjects: 0
Study 30565793 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/daily)
Number of subjects: 60
Study 30565793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28222555 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapulohumeral rehabilitation protocol (20 minutes per day, 5 days a week, for 6 weeks)
Number of subjects: 28
Study 28222555 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm rehabilitation (control group)
Number of subjects: 28
Study 26094050 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 1422
Study 26094050 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 1422
Study 24608196 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA100 + PALO 0.50 mg
Number of subjects: 694
Study 24608196 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA200 + PALO 0.50 mg
Number of subjects: 694
Study 24608196 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA300 + PALO 0.50 mg
Number of subjects: 694
Study 24608196 — intervention group
Group type: COMPARATOR
Intervention: PALO 0.50 mg
Number of subjects: 694
Study 24608196 — intervention group
Group type: EXPERIMENTAL
Intervention: APR + OND 32 mg
Number of subjects: 694
Study 22554092 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 152
Study 22554092 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 152
Study 19605373 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aquatic training (3 weekly sessions of 60 min for 32 weeks)
Number of subjects: 30
Study 19605373 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aquatic training
Number of subjects: 30
Study 19605373 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 17240136 — intervention group
Group type: EXPERIMENTAL
Intervention: IM‐MS irradiation
Number of subjects: 4004
Study 17240136 — intervention group
Group type: COMPARATOR
Intervention: No IM‐MS irradiation
Number of subjects: 4004
Study 15751168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 IU, daily subcutaneous injections for 14 days)
Number of subjects: 3681
Study 15751168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3681
Study 11788639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH (100 mcg/kg/day)
Number of subjects: 13
Study 11788639 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-GH treatment
Number of subjects: 13
Study 11788639 — intervention group
Group type: COMPARATOR
Intervention: Non-GH treated children
Number of subjects: 13
Study 10517552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (MOR) administration
Number of subjects: 9
Study 10517552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (MOR) administration
Number of subjects: 9
Study 7593423 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg, iv)
Number of subjects: 14
Study 7593423 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microgram/kg, iv)
Number of subjects: 14
Study 7593423 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-6
Number of subjects: 14
Study 2108196 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (1500 IU every 6 days)
Number of subjects: 10
Study 2108196 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (1500 IU every 6 days) + FSH (75 IU every 3 days)
Number of subjects: 10
Study 109598 — intervention group
Group type: EXPERIMENTAL
Intervention: Test regimen of prednisone therapy (higher dosage, longer duration)
Number of subjects: 54
Study 109598 — intervention group
Group type: COMPARATOR
Intervention: Standard prednisone relapse regimen
Number of subjects: 54
Study 31710930 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Pregnancy-Related Anxiety Questionnaire (PRAQ-R2) scores at gestational week 24
Number of subjects: 19
Study 31710930 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Pregnancy-Related Anxiety Questionnaire (PRAQ-R2) scores at gestational week 34
Number of subjects: 19
Study 31054292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokuyama Bond Force II™ adhesive system (Group 5)
Number of subjects: 105
Study 31054292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Self Etch™ adhesive system (Group 1)
Number of subjects: 105
Study 31054292 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐roughened and non‐conditioned surfaces (Group 3)
Number of subjects: 105
Study 31054292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting and Gluma Self Etch™ (Group 4)
Number of subjects: 105
Study 31054292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting only (Group 6)
Number of subjects: 105
Study 31054292 — intervention group
Group type: COMPARATOR
Intervention: Positive control group
Number of subjects: 105
Study 28673323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracelet- and self-directed observational therapy (BSDOT)
Number of subjects: 0
Study 28673323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 26519114 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist (spironolactone) in combination with RAAS blockers
Number of subjects: 71
Study 26519114 — intervention group
Group type: COMPARATOR
Intervention: Control group (RAAS blockers only)
Number of subjects: 71
Study 23587902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinogram affirmed iterative reconstruction (SAFIRE)
Number of subjects: 30
Study 23587902 — intervention group
Group type: COMPARATOR
Intervention: Filtered back projection (FBP)
Number of subjects: 30
Study 21170603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr brewer's yeast supplementation (500 μg Cr/person/day)
Number of subjects: 20
Study 21170603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19224907 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative quadriceps strength
Number of subjects: 73
Study 19224907 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative quadriceps strength deficits above 20%
Number of subjects: 73
Study 19224907 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscus injury
Number of subjects: 73
Study 19224907 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐Form‐36 Bodily Pain sub score
Number of subjects: 73
Study 17200492 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/day of zonisamide (ZNS)
Number of subjects: 0
Study 17200492 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day of zonisamide (ZNS)
Number of subjects: 0
Study 17200492 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of zonisamide (ZNS)
Number of subjects: 0
Study 17200492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15113269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 64
Study 15113269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 64
Study 15113269 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 64
Study 15113269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11403338 — intervention group
Group type: EXPERIMENTAL
Intervention: Past interaction frequency
Number of subjects: 320
Study 11403338 — intervention group
Group type: EXPERIMENTAL
Intervention: Future interaction frequency
Number of subjects: 320
Study 9761224 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin preload
Number of subjects: 24
Study 9761224 — intervention group
Group type: COMPARATOR
Intervention: No-maltodextrin control soup
Number of subjects: 24
Study 8052481 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 85
Study 8052481 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 85
Study 8052481 — intervention group
Group type: EXPERIMENTAL
Intervention: AG+MPA
Number of subjects: 85
Study 8052481 — intervention group
Group type: COMPARATOR
Intervention: AG, MPA, AG+MPA (all groups)
Number of subjects: 85
Study 2459557 — intervention group
Group type: EXPERIMENTAL
Intervention: Penticainide (1.5 mg/kg)
Number of subjects: 20
Study 2459557 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (1.5 mg/kg)
Number of subjects: 20
Study 31830433 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace for 2 weeks during daily living, sports, or painful tasks
Number of subjects: 50
Study 31830433 — intervention group
Group type: COMPARATOR
Intervention: Educational leaflet with information about PFP
Number of subjects: 50
Study 30556913 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interview intervention
Number of subjects: 46
Study 30556913 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 46
Study 30556913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (neural response to alcohol taste cues)
Number of subjects: 46
Study 28482740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 36
Study 28482740 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular resistance exercise program
Number of subjects: 36
Study 28482740 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobility exercise program
Number of subjects: 36
Study 28482740 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic-band program
Number of subjects: 36
Study 28482740 — intervention group
Group type: COMPARATOR
Intervention: Pedaling on a pedal exerciser
Number of subjects: 36
Study 28482740 — intervention group
Group type: COMPARATOR
Intervention: Mobility exercises
Number of subjects: 36
Study 26368295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 10 mg (oral dose)
Number of subjects: 6
Study 22499082 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diodes (LEDs)
Number of subjects: 1404
Study 22499082 — intervention group
Group type: EXPERIMENTAL
Intervention: Spotlights
Number of subjects: 1404
Study 22499082 — intervention group
Group type: EXPERIMENTAL
Intervention: Banks
Number of subjects: 1404
Study 22499082 — intervention group
Group type: EXPERIMENTAL
Intervention: Blankets
Number of subjects: 1404
Study 21292898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine pyrimetamine (SP)
Number of subjects: 0
Study 21292898 — intervention group
Group type: EXPERIMENTAL
Intervention: National IPTp implementation with sulfadoxine pyrimetamine (SP)
Number of subjects: 0
Study 21292898 — intervention group
Group type: COMPARATOR
Intervention: Pre-trial study with chloroquine prophylaxis
Number of subjects: 0
Study 18206425 — intervention group
Group type: EXPERIMENTAL
Intervention: OA self-management program
Number of subjects: 519
Study 18206425 — intervention group
Group type: COMPARATOR
Intervention: Health education (attention control)
Number of subjects: 519
Study 18206425 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 519
Study 16856588 — intervention group
Group type: EXPERIMENTAL
Intervention: Only vaginal misoprostol (400 microg 6 hourly up to 4 doses)
Number of subjects: 54
Study 16856588 — intervention group
Group type: COMPARATOR
Intervention: Oral plus vaginal misoprostol (400 microg orally at 12 hour intervals for 2 doses, followed by 400 microg vaginally 6 hourly up to 4 doses)
Number of subjects: 54
Study 14551000 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization table with numbers and categories
Number of subjects: 461
Study 14551000 — intervention group
Group type: COMPARATOR
Intervention: Food and Drug Administration table with numbers
Number of subjects: 461
Study 14551000 — intervention group
Group type: EXPERIMENTAL
Intervention: Category table
Number of subjects: 461
Study 11018309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo PGE1 injection
Number of subjects: 10
Study 11018309 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant rate infusion of PGE1 (10 ng kg(‐1) min(‐1))
Number of subjects: 10
Study 11018309 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant rate infusion of PGE1 (50 ng kg(‐1) min(‐1))
Number of subjects: 10
Study 11018309 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 10
Study 9296473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin dalteparin (Fragmin) for 3 months
Number of subjects: 3100
Study 9296473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3100
Study 9296473 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct invasive strategy
Number of subjects: 3100
Study 9296473 — intervention group
Group type: COMPARATOR
Intervention: Stepwise selective approach
Number of subjects: 3100
Study 9296473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin dalteparin (Fragmin)
Number of subjects: 3100
Study 7690219 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg/d (bid)
Number of subjects: 14
Study 7690219 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg/d (tid)
Number of subjects: 14
Study 7690219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3519976 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 0
Study 3519976 — intervention group
Group type: COMPARATOR
Intervention: Attention-education
Number of subjects: 0
Study 3519976 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 31618115 — intervention group
Group type: EXPERIMENTAL
Intervention: PICO dressing
Number of subjects: 188
Study 31618115 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 188
Study 30057892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (exercise 1 h, twice weekly; education 1 h, once weekly)
Number of subjects: 16
Study 30057892 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 16
Study 27756928 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL)
Number of subjects: 30
Study 27756928 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 30
Study 26227393 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean amplitude of glycemic excursion (MAGE) measured using continuous glucose monitoring system (CGMS)
Number of subjects: 88
Study 26227393 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE as an independent predictor of rapid progression (RP)
Number of subjects: 88
Study 22475430 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute watercress supplementation (consumption 2 h before exercise)
Number of subjects: 10
Study 22475430 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic watercress supplementation (8 weeks consumption)
Number of subjects: 10
Study 22475430 — intervention group
Group type: COMPARATOR
Intervention: Control (no ingestion)
Number of subjects: 10
Study 21122057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 150/12.5mg
Number of subjects: 688
Study 21122057 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 150mg
Number of subjects: 688
Study 21122057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT
Number of subjects: 688
Study 21122057 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren
Number of subjects: 688
Study 18468543 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST intervention (peer-led smoking prevention program)
Number of subjects: 10730
Study 16644344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 463
Study 16644344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 12715402 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11012557 — intervention group
Group type: EXPERIMENTAL
Intervention: Z13752A 200 mg
Number of subjects: 16
Study 11012557 — intervention group
Group type: EXPERIMENTAL
Intervention: Z13752A 400 mg
Number of subjects: 16
Study 11012557 — intervention group
Group type: EXPERIMENTAL
Intervention: Z13752A 600 mg
Number of subjects: 16
Study 11012557 — intervention group
Group type: EXPERIMENTAL
Intervention: Z13752A 800 mg
Number of subjects: 16
Study 11012557 — intervention group
Group type: EXPERIMENTAL
Intervention: Z13752A (all doses tested)
Number of subjects: 16
Study 11012557 — intervention group
Group type: EXPERIMENTAL
Intervention: Z13752A (200-800 mg range)
Number of subjects: 16
Study 11012557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8697547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms.ml‐1 with bupivacaine 0.015% and epinephrine 2 micrograms.ml‐1
Number of subjects: 100
Study 8697547 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 1 microgram.ml‐1 with bupivacaine 0.015% and epinephrine 2 micrograms.ml‐1
Number of subjects: 100
Study 1384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestine only
Number of subjects: 17
Study 1384443 — intervention group
Group type: COMPARATOR
Intervention: Liver-intestine
Number of subjects: 17
Study 1384443 — intervention group
Group type: COMPARATOR
Intervention: Multivisceral graft
Number of subjects: 17
Study 1384443 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall transplantation
Number of subjects: 17
Study 1384443 — intervention group
Group type: COMPARATOR
Intervention: Intestinal anastomotic leak
Number of subjects: 17
Study 6435443 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (infused intravenously)
Number of subjects: 5
Study 6435443 — intervention group
Group type: COMPARATOR
Intervention: Intragastric nutrition (infused intragastrically)
Number of subjects: 5